Please login to the form below

Not currently logged in
Email:
Password:

Next OTC statin doubted

Merck and Johnson and Johnson's bid to sell a cholesterol-lowering drug as OTC has been rejected by a US regulatory advisory panel.

Merck and Johnson and Johnson's bid to sell Mevacor, a cholesterol-lowering drug, as an over-the-counter, non-prescription medicine, was rejected by a US regulatory advisory panel by a mammoth vote of 20-3.

The Food and Drug Administration is likely to accept the panel's decision, which determined that the low dose version of Mevacor, part of the statin class of drugs used to lower cholesterol and heart disease risk, should not be sold without a prescription due to safety fears. The panel advised that patients should interact with a doctor to ensure they use the medication safely and effectively. In particular, the drug could cause birth defects and would be easily accessible to pregnant women, it was noted.

The approval of Mevacor for OTC status could have seen the opening of the floodgates for a whole wealth of medications for chronic, potentially life-threatening diseases to be sold in pharmacies. Indeed, the rejection is a setback to the pharma industry's efforts to target medications for chronic illnesses directly to the consumer. Last year, Merck gained approval to sell Zocor, another statin, to consumers in the UK who have to ask a pharmacist for it from 'behind the counter'. The news is also bleak for Bristol-Myers Squibb which had proposed to ask the FDA for approval to sell statin, Pravachol, as an OTC.

One argument for OTC statins was that evidence showed that more Americans needed to lower their cholesterol, and therefore statins could help improve national health, although critics have countered that potential patients should first consult a doctor.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics